![David Sheppard](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David Sheppard
Director/Board Member at Locki Therapeutics Ltd.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Anastasia Callaghan | M | 50 |
Revona Bio Ltd.
![]() Revona Bio Ltd. Miscellaneous Commercial ServicesCommercial Services Revona Bio Ltd. is a British biotechnology company that specializes in the development of RNA targeted drugs. The company was founded in 2022 by Anastasia Jane Callaghan and Charlotte Anne Henderson. | 2 years |
Charlotte Henderson | F | 39 |
Revona Bio Ltd.
![]() Revona Bio Ltd. Miscellaneous Commercial ServicesCommercial Services Revona Bio Ltd. is a British biotechnology company that specializes in the development of RNA targeted drugs. The company was founded in 2022 by Anastasia Jane Callaghan and Charlotte Anne Henderson. | 2 years |
Ian Gilham | M | 64 |
Revona Bio Ltd.
![]() Revona Bio Ltd. Miscellaneous Commercial ServicesCommercial Services Revona Bio Ltd. is a British biotechnology company that specializes in the development of RNA targeted drugs. The company was founded in 2022 by Anastasia Jane Callaghan and Charlotte Anne Henderson. | - |
Andrew Sinclair | M | 52 |
Locki Therapeutics Ltd.
![]() Locki Therapeutics Ltd. BiotechnologyHealth Technology Locki Therapeutics Ltd. is a British preclinical stage biotechnology company founded in 2019. The company is based in London, UK. Locki Therapeutics is developing a new class of drugs that enhance the function of beneficial proteins. The company has designed its proprietary encompass™ platform to create enhancement-targeting chimeric (entac™) medicines. These entacs harness the ability of dubs to regulate proteins, expanding the universe of treatable diseases. | - |
Alon Lazarus | M | 49 |
Locki Therapeutics Ltd.
![]() Locki Therapeutics Ltd. BiotechnologyHealth Technology Locki Therapeutics Ltd. is a British preclinical stage biotechnology company founded in 2019. The company is based in London, UK. Locki Therapeutics is developing a new class of drugs that enhance the function of beneficial proteins. The company has designed its proprietary encompass™ platform to create enhancement-targeting chimeric (entac™) medicines. These entacs harness the ability of dubs to regulate proteins, expanding the universe of treatable diseases. | - |
Richard Gaster | M | 40 |
Locki Therapeutics Ltd.
![]() Locki Therapeutics Ltd. BiotechnologyHealth Technology Locki Therapeutics Ltd. is a British preclinical stage biotechnology company founded in 2019. The company is based in London, UK. Locki Therapeutics is developing a new class of drugs that enhance the function of beneficial proteins. The company has designed its proprietary encompass™ platform to create enhancement-targeting chimeric (entac™) medicines. These entacs harness the ability of dubs to regulate proteins, expanding the universe of treatable diseases. | - |
Owen Smith | M | - |
Locki Therapeutics Ltd.
![]() Locki Therapeutics Ltd. BiotechnologyHealth Technology Locki Therapeutics Ltd. is a British preclinical stage biotechnology company founded in 2019. The company is based in London, UK. Locki Therapeutics is developing a new class of drugs that enhance the function of beneficial proteins. The company has designed its proprietary encompass™ platform to create enhancement-targeting chimeric (entac™) medicines. These entacs harness the ability of dubs to regulate proteins, expanding the universe of treatable diseases. | 4 years |
Owen Philip Smith | M | 38 |
Locki Therapeutics Ltd.
![]() Locki Therapeutics Ltd. BiotechnologyHealth Technology Locki Therapeutics Ltd. is a British preclinical stage biotechnology company founded in 2019. The company is based in London, UK. Locki Therapeutics is developing a new class of drugs that enhance the function of beneficial proteins. The company has designed its proprietary encompass™ platform to create enhancement-targeting chimeric (entac™) medicines. These entacs harness the ability of dubs to regulate proteins, expanding the universe of treatable diseases. | - |
Edward McGill | M | - |
Locki Therapeutics Ltd.
![]() Locki Therapeutics Ltd. BiotechnologyHealth Technology Locki Therapeutics Ltd. is a British preclinical stage biotechnology company founded in 2019. The company is based in London, UK. Locki Therapeutics is developing a new class of drugs that enhance the function of beneficial proteins. The company has designed its proprietary encompass™ platform to create enhancement-targeting chimeric (entac™) medicines. These entacs harness the ability of dubs to regulate proteins, expanding the universe of treatable diseases. | 5 years |
Colin Walsh | M | 39 |
Locki Therapeutics Ltd.
![]() Locki Therapeutics Ltd. BiotechnologyHealth Technology Locki Therapeutics Ltd. is a British preclinical stage biotechnology company founded in 2019. The company is based in London, UK. Locki Therapeutics is developing a new class of drugs that enhance the function of beneficial proteins. The company has designed its proprietary encompass™ platform to create enhancement-targeting chimeric (entac™) medicines. These entacs harness the ability of dubs to regulate proteins, expanding the universe of treatable diseases. | - |
Jeremy Howells | M | 68 |
Revona Bio Ltd.
![]() Revona Bio Ltd. Miscellaneous Commercial ServicesCommercial Services Revona Bio Ltd. is a British biotechnology company that specializes in the development of RNA targeted drugs. The company was founded in 2022 by Anastasia Jane Callaghan and Charlotte Anne Henderson. | - |
Jason Mellad | M | 42 |
Revona Bio Ltd.
![]() Revona Bio Ltd. Miscellaneous Commercial ServicesCommercial Services Revona Bio Ltd. is a British biotechnology company that specializes in the development of RNA targeted drugs. The company was founded in 2022 by Anastasia Jane Callaghan and Charlotte Anne Henderson. | - |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
United Kingdom | 12 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- David Sheppard
- Personal Network